CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer

Published:2021-01-29 Issue:6 Volume:126 Page:786-794
ISSN:0033-8362
Container-title:La radiologia medica
language:en
Short-container-title:Radiol med

Author:

Agazzi Giorgio Maria,Ravanelli Marco,Roca Elisa,Medicina Daniela,Balzarini Piera,Pessina Carlotta^ORCID,Vermi William,Berruti Alfredo,Maroldi Roberto,Farina Davide

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11547-020-01323-7.pdf

Reference30 articles.

1. Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(524):548. https://doi.org/10.1001/jamaoncol.2016.5688

2. Barlesi F, Mazieres J, Merlio J-P et al (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the french cooperative thoracic intergroup (IFCT). The Lancet 387:1415–1426. https://doi.org/10.1016/S0140-6736(16)00004-0

3. Hanna N, Johnson D, Temin S et al (2017) Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. JCO 35:3484–3515. https://doi.org/10.1200/JCO.2017.74.6065

4. Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27. https://doi.org/10.1093/annonc/mdw326

5. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246. https://doi.org/10.1016/S1470-2045(11)70393-X

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Application of CT radiomics in brain metastasis of lung cancer: A systematic review and meta-analysis”;Clinical Imaging;2024-10

2. Three-dimensional iodine mapping quantified by dual-energy CT for predicting programmed death-ligand 1 expression in invasive pulmonary adenocarcinoma;Scientific Reports;2024-08-07

3. Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context;Academic Radiology;2024-07

4. Predicting MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma by whole-tumour texture analysis combined with clinical and conventional contrast-enhanced computed tomography features;Translational Lung Cancer Research;2024-06

5. Prediction of oncogene mutation status in non-small cell lung cancer: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods;2024-05-31